Do analysts rate ARTV or XBIT?

Artiva Biotherapeutics currently has a consensus price target of $39.00, suggesting a potential upside of 240.61%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARTV or XBIT more profitable?

XBiotech's return on equity of -30.60% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% XBiotech N/A -30.60% -29.28%

Does the media refer more to ARTV or XBIT?

In the previous week, Artiva Biotherapeutics had 9 more articles in the media than XBiotech. MarketBeat recorded 12 mentions for Artiva Biotherapeutics and 3 mentions for XBiotech. Artiva Biotherapeutics' average media sentiment score of 0.53 beat XBiotech's score of -0.14 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CLLS or XBIT?

Cellectis presently has a consensus target price of $7.00, suggesting a potential upside of 129.51%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CLLS or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. XBiotech's return on equity of -30.60% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% XBiotech N/A -30.60% -29.28%

Does the media prefer CLLS or XBIT?

In the previous week, Cellectis and Cellectis both had 3 articles in the media. Cellectis' average media sentiment score of 0.78 beat XBiotech's score of -0.14 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XBIT or ANIK?

Anika Therapeutics has a consensus price target of $21.00, indicating a potential downside of 2.33%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media prefer XBIT or ANIK?

In the previous week, XBiotech had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 3 mentions for XBiotech and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.98 beat XBiotech's score of -0.14 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EDIT or XBIT?

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 91.49%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EDIT or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. XBiotech's return on equity of -30.60% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Editas Medicine -157.32% -196.63% -38.17% XBiotech N/A -30.60% -29.28%

Does the media refer more to EDIT or XBIT?

In the previous week, Editas Medicine had 11 more articles in the media than XBiotech. MarketBeat recorded 14 mentions for Editas Medicine and 3 mentions for XBiotech. Editas Medicine's average media sentiment score of 0.88 beat XBiotech's score of -0.14 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XBIT or TRDA?

Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 137.94%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer XBIT or TRDA?

In the previous week, Entrada Therapeutics had 18 more articles in the media than XBiotech. MarketBeat recorded 21 mentions for Entrada Therapeutics and 3 mentions for XBiotech. Entrada Therapeutics' average media sentiment score of 0.21 beat XBiotech's score of -0.14 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

XBiotech (XBIT) Competitors

$2.30 -0.03 (-1.29%)

Closing price 03:59 PM Eastern

Extended Trading

$2.33 +0.03 (+1.30%)

As of 04:10 PM Eastern

Compare

XBIT vs. ARTV, CLLS, ANIK, EDIT, and TRDA

Should you buy XBiotech stock or one of its competitors? XBiotech's main competitors and comparable companies include Artiva Biotherapeutics (ARTV), Cellectis (CLLS), Anika Therapeutics (ANIK), Editas Medicine (EDIT), and Entrada Therapeutics (TRDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XBiotech compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Artiva Biotherapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Artiva Biotherapeutics currently has a consensus price target of $39.00, suggesting a potential upside of 240.61%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

55.7% of XBiotech shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

XBiotech's return on equity of -30.60% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
XBiotech	N/A	-30.60%	-29.28%

In the previous week, Artiva Biotherapeutics had 9 more articles in the media than XBiotech. MarketBeat recorded 12 mentions for Artiva Biotherapeutics and 3 mentions for XBiotech. Artiva Biotherapeutics' average media sentiment score of 0.53 beat XBiotech's score of -0.14 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XBiotech has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	2,239.16	-$83.86M	-$3.30	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

Summary

Artiva Biotherapeutics beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Cellectis?

Cellectis (NASDAQ:CLLS) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Cellectis presently has a consensus target price of $7.00, suggesting a potential upside of 129.51%. Given Cellectis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectis is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. XBiotech's return on equity of -30.60% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
XBiotech	N/A	-30.60%	-29.28%

XBiotech has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.85	-$67.59M	-$0.65	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

63.9% of Cellectis shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cellectis and Cellectis both had 3 articles in the media. Cellectis' average media sentiment score of 0.78 beat XBiotech's score of -0.14 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cellectis beats XBiotech on 10 of the 15 factors compared between the two stocks.

How does XBiotech compare to Anika Therapeutics?

XBiotech (NASDAQ:XBIT) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

XBiotech has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-30.60%	-29.28%
Anika Therapeutics	-3.14%	0.20%	0.15%

XBiotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has a consensus price target of $21.00, indicating a potential downside of 2.33%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Anika Therapeutics has higher revenue and earnings than XBiotech. Anika Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Anika Therapeutics	$112.82M	2.55	-$10.88M	-$0.27	N/A

In the previous week, XBiotech had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 3 mentions for XBiotech and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.98 beat XBiotech's score of -0.14 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anika Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Anika Therapeutics beats XBiotech on 11 of the 16 factors compared between the two stocks.

How does XBiotech compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Editas Medicine had 11 more articles in the media than XBiotech. MarketBeat recorded 14 mentions for Editas Medicine and 3 mentions for XBiotech. Editas Medicine's average media sentiment score of 0.88 beat XBiotech's score of -0.14 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XBiotech has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.69	-$160.06M	-$0.75	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

XBiotech has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. XBiotech's return on equity of -30.60% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
XBiotech	N/A	-30.60%	-29.28%

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 91.49%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Editas Medicine beats XBiotech on 9 of the 15 factors compared between the two stocks.

How does XBiotech compare to Entrada Therapeutics?

XBiotech (NASDAQ:XBIT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

XBiotech has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. XBiotech's return on equity of -30.60% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-30.60%	-29.28%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

XBiotech has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Entrada Therapeutics	$25.42M	11.43	-$143.75M	-$3.96	N/A

XBiotech has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Entrada Therapeutics had 18 more articles in the media than XBiotech. MarketBeat recorded 21 mentions for Entrada Therapeutics and 3 mentions for XBiotech. Entrada Therapeutics' average media sentiment score of 0.21 beat XBiotech's score of -0.14 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 137.94%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

XBiotech beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.04M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.55	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.50	16.78	12.91	6.24
Net Income	-$45.54M	-$13.32M	$3.45B	$347.60M
7 Day Performance	1.32%	1.74%	1.12%	1.07%
1 Month Performance	0.44%	1.60%	1.79%	1.03%
1 Year Performance	-29.01%	56.43%	67.69%	20.77%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	0.4226 of 5 stars	$2.30 -1.3%	N/A	-25.8%	$71.04M	N/A	N/A	100	News Coverage Earnings Report
ARTV Artiva Biotherapeutics	2.8195 of 5 stars	$11.78 +5.0%	$39.00 +231.1%	+323.2%	$277.33M	N/A	N/A	81	Analyst Revision
CLLS Cellectis	2.3649 of 5 stars	$2.89 +4.7%	$7.00 +142.2%	+14.0%	$276.94M	$79.59M	N/A	290
ANIK Anika Therapeutics	3.4001 of 5 stars	$21.23 +2.7%	$21.00 -1.1%	+133.1%	$276.76M	$112.82M	N/A	300
EDIT Editas Medicine	2.3804 of 5 stars	$2.95 +5.0%	$5.40 +83.1%	-8.8%	$275.12M	$40.52M	N/A	230	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. ARTV, CLLS, ANIK, EDIT, and TRDA

How does XBiotech compare to Artiva Biotherapeutics?

Summary

How does XBiotech compare to Cellectis?

Summary

How does XBiotech compare to Anika Therapeutics?

Summary

How does XBiotech compare to Editas Medicine?

Summary

How does XBiotech compare to Entrada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. ARTV, CLLS, ANIK, EDIT, and TRDA

How does XBiotech compare to Artiva Biotherapeutics?

Which has more risk & volatility, ARTV or XBIT?

Do analysts rate ARTV or XBIT?

Do insiders and institutionals have more ownership in ARTV or XBIT?

Is ARTV or XBIT more profitable?

Does the media refer more to ARTV or XBIT?

Which has higher earnings & valuation, ARTV or XBIT?

Summary

How does XBiotech compare to Cellectis?

Do analysts rate CLLS or XBIT?

Which has more risk & volatility, CLLS or XBIT?

Is CLLS or XBIT more profitable?

Which has preferable earnings & valuation, CLLS or XBIT?

Do insiders and institutionals hold more shares of CLLS or XBIT?

Does the media prefer CLLS or XBIT?

Summary

How does XBiotech compare to Anika Therapeutics?

Do insiders and institutionals believe in XBIT or ANIK?

Is XBIT or ANIK more profitable?

Which has more volatility and risk, XBIT or ANIK?

Do analysts recommend XBIT or ANIK?

Which has higher valuation & earnings, XBIT or ANIK?

Does the media prefer XBIT or ANIK?

Summary

How does XBiotech compare to Editas Medicine?

Do institutionals and insiders believe in EDIT or XBIT?

Does the media refer more to EDIT or XBIT?

Which has preferable earnings and valuation, EDIT or XBIT?

Is EDIT or XBIT more profitable?

Which has more risk and volatility, EDIT or XBIT?

Do analysts recommend EDIT or XBIT?

Summary

How does XBiotech compare to Entrada Therapeutics?

Is XBIT or TRDA more profitable?

Which has higher valuation and earnings, XBIT or TRDA?

Which has more volatility and risk, XBIT or TRDA?

Do insiders & institutionals believe in XBIT or TRDA?

Does the media prefer XBIT or TRDA?

Do analysts rate XBIT or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools